EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Novartis AG – NVS
- 122
Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Novartis AG (NYSE: NVS) resulting from allegations that the board of directors of Novartis may have breached its fiduciary duties to shareholders.
On June 25, 2020, the Company agreed to pay $225 million in criminal fines and disgorge $112 million in settling bribery allegations brought forth by the U.S. Department of Justice and the Securities and Exchange Commission. Novartis was under investigation for claims that: (1) the Company had bribed doctors and hospitals in Greece to prescribe “Novartis-branded pharmaceuticals”; (2) the Company had paid bribes in Vietnam to advance their business; and (3) the Company had falsified their financial records to conceal said activities. On this news, the Company’s share prices dropped by $2.50 over the following trading session.
Rosen Law Firm is preparing a securities lawsuit on behalf of Novartis shareholders. If you purchased securities of Novartis please visit the firm’s website at http://www.rosenlegal.com/cases-register-1887.html to join the securities action. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has secured hundreds of millions of dollars for investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200626005535/en/
